ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1274

Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol

Elena Joerns1, Nagendra Pokala2, Dan Wang3, Joan Reisch3, Reuben Arasaratnam3, Bonnie Bermas1 and Puneet Bajaj3, 1UT Southwestern, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Infection, prevention, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines recommends that immunocompromised adults aged ≥19 years receive the pneumococcal conjugate (PCV13) vaccine followed by the pneumococcal polysaccharide (PPSV23) vaccine. Our goal was to implement a nurse-driven protocol to 1) increase combined PCV13 and PPSV23 monthly vaccination rates in immunosuppressed patients aged 19-64 years old and 2) increase the overall proportion of immunosuppressed patients aged 19-64 years old who have received both PCV13 and PPSV23 vaccinations at the University of Texas Southwestern Rheumatic Diseases clinic over a two-year period.

Methods: We identified eligible adults aged 19-64 years old in the Electronic Medical Record (EMR) using a search protocol based on pre-set medication group. We obtained baseline pneumococcal vaccination rates from January 1, 2019 to December 31, 2019. We calculated the proportion of patients who were unvaccinated, partially vaccinated (received either PCV13 or PPSV23), or fully vaccinated. We developed a nurse-driven workflow for vaccination implementation in the clinic. Using Center for Disease Control (CDC) guidelines, we created a pneumococcal vaccination protocol and converted it into a university approved Standing Medical Order (SMO) to be used by the nursing staff. Post-intervention pneumococcal vaccination rates and proportions were calculated on a monthly basis and at the end of the study period. Monthly meetings were conducted to address new problems or concerns.

Results: The post-intervention period started on January 1, 2020. COVID-19 pandemic with associated clinic closures and workflow changes led to significant decline in vaccination rates. Vaccination rates also declined both after COVID-19 vaccines became available to patients and after the surge of COVID-19 cases due to the B.1.617.2 (Delta) variant of SARS-CoV-2. Despite that, we increased the proportion of patients who were fully vaccinated by the end of the year from baseline of 14.6% in 2019 to 19.1% in 2020 and 26.2% in 2021 (Figure 1). We also improved the rate of monthly vaccination from 6.3% to 14.5% by Dec 2021 (Figure 2).

Conclusion: Our clinic employed a nurse-driven SMO protocol that led to improvement in pneumococcal vaccination rates. The COVID-19 pandemic has provided a significant barrier to pneumococcal vaccination efforts for multiple reasons, including reduction in in-person visits, changes in clinic protocols, and providing competing priorities.

Supporting image 1

Figure 1: Proportion of patients seen who were partially or fully vaccinated by the end of the year increased during the study period.

Supporting image 2

Figure 2: COVID_19 related clinic closures affected pneumococcal vaccination rates in eligible patients.


Disclosures: E. Joerns, Pfizer, Inc; N. Pokala, None; D. Wang, None; J. Reisch, None; R. Arasaratnam, None; B. Bermas, Bristol-Myers Squibb(BMS), Novartis; P. Bajaj, None.

To cite this abstract in AMA style:

Joerns E, Pokala N, Wang D, Reisch J, Arasaratnam R, Bermas B, Bajaj P. Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/improving-pneumococcal-vaccination-rates-among-immunosuppressed-adults-in-an-academic-rheumatology-clinic-utilizing-a-nurse-driven-protocol-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-pneumococcal-vaccination-rates-among-immunosuppressed-adults-in-an-academic-rheumatology-clinic-utilizing-a-nurse-driven-protocol-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology